Yes, Belbuca is legally classified as a narcotic. The Drug Enforcement Administration (DEA) specifically designates it a Schedule III narcotic under the Controlled Substances Act. That said, Belbuca works differently from the opioids most people picture when they hear the word “narcotic,” and those differences matter for both safety and addiction risk.
What Belbuca Is and How It’s Used
Belbuca is a small dissolvable film containing buprenorphine, a type of opioid. You place the film inside your cheek, where it dissolves and delivers the medication through the lining of your mouth. It comes in seven strengths, ranging from 75 to 900 micrograms.
The FDA approved Belbuca for severe, persistent pain that can’t be adequately managed with other options, including immediate-release opioids. It’s not designed for occasional or as-needed pain relief. It’s a long-acting medication prescribed for around-the-clock pain management in people who have already tried and failed other treatments. Prescribers are expected to assess each patient’s risk for addiction before starting it and to use the lowest effective dose for the shortest time needed.
Why It’s Called a Narcotic but Acts Differently
Under federal law, “narcotic” has a specific legal meaning: it refers to opioids and certain other substances regulated under the Controlled Substances Act. By that definition, Belbuca qualifies. But the way buprenorphine behaves in the body sets it apart from full-strength narcotics like morphine, oxycodone, or fentanyl.
Those drugs are full agonists, meaning they fully activate opioid receptors in the brain. The more you take, the stronger the effect, including the dangerous slowing of breathing that causes most opioid overdose deaths. Buprenorphine is a partial agonist. It activates the same receptors, but only partway. There’s a built-in ceiling: after a certain dose, taking more doesn’t produce a proportionally stronger effect.
This ceiling is especially important for breathing. In a study of healthy volunteers given two different intravenous doses of buprenorphine (one double the other), respiratory depression was nearly identical between the two groups. Doubling the dose didn’t meaningfully increase the suppression of breathing, even though pain relief continued to improve. Full agonist opioids don’t work this way. With morphine or fentanyl, higher doses keep pushing breathing lower, which is why overdose can be fatal.
Schedule III vs. Schedule II
The DEA’s scheduling system ranks drugs partly by their potential for abuse. Schedule II includes the most tightly controlled prescription drugs: oxycodone, fentanyl, morphine, and hydrocodone. These carry the highest abuse and addiction risk among legally prescribed medications. Buprenorphine was originally placed in Schedule V (the lowest restriction level) and was later moved up to Schedule III in 2002, after the DEA determined it had a higher abuse potential than initially thought.
Still, Schedule III sits below Schedule II. The DEA’s formal findings state that buprenorphine has a potential for abuse less than Schedule II drugs, a currently accepted medical use, and that its abuse may lead to moderate or low physical dependence or high psychological dependence. In practical terms, this means Belbuca prescriptions can be refilled up to five times within six months, while Schedule II opioids require a new prescription each time.
How Buprenorphine Blocks Other Opioids
One unusual property of buprenorphine is how tightly it grips opioid receptors. It binds with high affinity and releases very slowly. This means it can actually block stronger opioids from attaching to those same receptors. If someone taking Belbuca were to use a full-agonist opioid like morphine, the morphine would have a harder time producing its usual effect because buprenorphine is already occupying the receptor sites.
This blocking property is part of why buprenorphine is also used (in different formulations and doses) to treat opioid addiction. It reduces cravings and withdrawal symptoms while making it harder to get high from other opioids. Belbuca itself is not approved for addiction treatment, but its active ingredient is the same drug used in those settings.
Risks That Still Apply
Being a partial agonist doesn’t make Belbuca risk-free. The FDA’s prescribing information carries warnings about addiction, abuse, misuse, overdose, and death, noting these risks exist at any dosage and throughout the course of treatment. People with a personal or family history of substance abuse, or those with mental health conditions like major depression, face higher risk.
The ceiling effect on breathing also has limits. Combining buprenorphine with alcohol, benzodiazepines (anti-anxiety medications), or other sedating drugs can override that safety margin and cause dangerous respiratory depression. The ceiling applies to buprenorphine alone, not necessarily in combination with other substances that suppress breathing through different pathways.
Physical dependence develops with regular use, just as it does with other opioids. Stopping Belbuca abruptly after extended use causes withdrawal symptoms, though these tend to be milder and more gradual than withdrawal from full-agonist opioids, thanks to buprenorphine’s slow release from receptors.
The Short Answer
Belbuca is a narcotic by every legal and pharmacological definition. It contains an opioid, it’s a controlled substance, and it carries real risks of dependence and misuse. But it occupies a middle ground in the opioid landscape: stronger pain relief than over-the-counter options, with a built-in safety ceiling and lower abuse potential than the Schedule II narcotics most people associate with the term.